CS340189A2 - Method of bivalent platinum derivatives production with polyanion of deoxyribonucleic acid - Google Patents

Method of bivalent platinum derivatives production with polyanion of deoxyribonucleic acid Download PDF

Info

Publication number: CS340189A2
Authority: CS; Czechoslovakia
Prior art keywords: compound; compounds; solution; animals; tumor
Prior art date: 1988-06-06

Application number

CS893401A

Other languages

Czech (cs)

English (en)

Inventor

Ilima Iliodorovna Volcenskova

Nadezda Nikolajevna Majdanevic

Lev Ivanovic Budarin

Jelena Petrovna Trochimenko

Ljudvig Vladislavovic Kejsevic

Sergej Alexandrovic Salimov

Sergej Nikolajevic Kopytin

Original Assignee

Inst Fiz Khim Pisarzhev An

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-06

Filing date

1989-06-05

Publication date

1990-10-12

1989-06-05 Application filed by Inst Fiz Khim Pisarzhev An filed Critical Inst Fiz Khim Pisarzhev An

1990-10-12 Publication of CS340189A2 publication Critical patent/CS340189A2/cs

Links

238000000034 method Methods 0.000 title claims description 20
102000053602 DNA Human genes 0.000 title claims description 8
108020004414 DNA Proteins 0.000 title claims description 8
150000003057 platinum Chemical class 0.000 title claims description 5
238000004519 manufacturing process Methods 0.000 title claims description 4
229920000447 polyanionic polymer Polymers 0.000 title claims description 3
150000001875 compounds Chemical class 0.000 claims description 74
230000008569 process Effects 0.000 claims description 14
238000002844 melting Methods 0.000 claims description 6
230000008018 melting Effects 0.000 claims description 6
239000012736 aqueous medium Substances 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 3
241001465754 Metazoa Species 0.000 description 34
239000000243 solution Substances 0.000 description 33
239000000126 substance Substances 0.000 description 25
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
206010028980 Neoplasm Diseases 0.000 description 21
238000002360 preparation method Methods 0.000 description 17
210000004027 cell Anatomy 0.000 description 16
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 13
239000000203 mixture Substances 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
230000000694 effects Effects 0.000 description 11
238000002211 ultraviolet spectrum Methods 0.000 description 11
238000011282 treatment Methods 0.000 description 10
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 9
230000000118 anti-neoplastic effect Effects 0.000 description 9
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
239000002253 acid Substances 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
241000700159 Rattus Species 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 7
239000012467 final product Substances 0.000 description 7
230000004727 humoral immunity Effects 0.000 description 7
210000000952 spleen Anatomy 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
206010033128 Ovarian cancer Diseases 0.000 description 6
206010061535 Ovarian neoplasm Diseases 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
239000000969 carrier Substances 0.000 description 6
230000007969 cellular immunity Effects 0.000 description 6
150000001860 citric acid derivatives Chemical class 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000001509 sodium citrate Substances 0.000 description 6
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
230000003530 immunodepressant effect Effects 0.000 description 5
201000007270 liver cancer Diseases 0.000 description 5
208000014018 liver neoplasm Diseases 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000012266 salt solution Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
238000005303 weighing Methods 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000002329 infrared spectrum Methods 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
231100000816 toxic dose Toxicity 0.000 description 4
IGBRRSIHEGCUEN-UHFFFAOYSA-N 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine Chemical compound C=1C=CC=CC=1CC(C=1C=CC=CC=1)N(CC1)CCN1C1CCCCC1 IGBRRSIHEGCUEN-UHFFFAOYSA-N 0.000 description 3
102100031090 Alpha-catulin Human genes 0.000 description 3
102100027267 FERM, ARHGEF and pleckstrin domain-containing protein 1 Human genes 0.000 description 3
101000922043 Homo sapiens Alpha-catulin Proteins 0.000 description 3
101000914701 Homo sapiens FERM, ARHGEF and pleckstrin domain-containing protein 1 Proteins 0.000 description 3
230000004520 agglutination Effects 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002519 immonomodulatory effect Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229910052697 platinum Inorganic materials 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
108010006464 Hemolysin Proteins Proteins 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003228 hemolysin Substances 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
230000036039 immunity Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000012770 revaccination Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
101710186708 Agglutinin Proteins 0.000 description 1
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000282817 Bovidae Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
239000004287 Dehydroacetic acid Substances 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
101710146024 Horcolin Proteins 0.000 description 1
101710189395 Lectin Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
101710179758 Mannose-specific lectin Proteins 0.000 description 1
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
101100327347 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDD1 gene Proteins 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000910 agglutinin Substances 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
-1 compound compound Chemical class 0.000 description 1
230000034994 death Effects 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000007340 echolocation Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000003082 hepatotoxic effect Effects 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
208000020082 intraepithelial neoplasia Diseases 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000036407 pain Effects 0.000 description 1
QOQNHEGRZYNCJV-UHFFFAOYSA-N phosphono (2,4,4-trimethylcyclohexen-1-yl)methyl hydrogen phosphate Chemical compound CC1=C(COP(O)(=O)OP(O)(O)=O)CCC(C)(C)C1 QOQNHEGRZYNCJV-UHFFFAOYSA-N 0.000 description 1
HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
150000003839 salts Chemical group 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008279 sol Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
102000014898 transaminase activity proteins Human genes 0.000 description 1
ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CS893401A 1988-06-06 1989-06-05 Method of bivalent platinum derivatives production with polyanion of deoxyribonucleic acid CS340189A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SU884437541A SU1685944A1 (ru)	1988-06-06	1988-06-06	Способ получени комплексного соединени платины (II) с высокомолекул рной н-ДНК из селезенки крупного рогатого скота марки А, обладающего противоопухолевой активностью

Publications (1)

Publication Number	Publication Date
CS340189A2 true CS340189A2 (en)	1990-10-12

Family

ID=21380063

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS893401A CS340189A2 (en)	1988-06-06	1989-06-05	Method of bivalent platinum derivatives production with polyanion of deoxyribonucleic acid

Country Status (7)

Country	Link
EP (1)	EP0374267A1 (ja)
JP (1)	JPH03501385A (ja)
CN (1)	CN1040202A (ja)
CS (1)	CS340189A2 (ja)
FI (1)	FI900565A7 (ja)
SU (1)	SU1685944A1 (ja)
WO (1)	WO1989011861A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2165937C2 (ru) *	1997-04-23	2001-04-27	Петербургский институт ядерной физики им. Б.П.Константинова РАН	Полирибонуклеотидный дуплекс на основе полирибоаденилата и полирибоуридилата

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5851959B2 (ja) *	1980-06-11	1983-11-19	呉羽化学工業株式会社	プラチナ化合物とその医薬組成物
US4758588A (en) *	1983-06-20	1988-07-19	Research Corporation Technologies	Diaminocyclohexane platinum complexes
US4544759A (en) *	1983-07-29	1985-10-01	American Cyanamid Company	Platinum complexes of antitumor agents
EP0210291A1 (en) *	1985-07-27	1987-02-04	American Cyanamid Company	Platinum complexes of antitumor agents
US4748254A (en) *	1984-01-23	1988-05-31	Institut Obschei I Neorganicheskoi Khimii Imeni N.S. Kurnakova Akademii Nauk SSR	Mixed carboxylato platinum (II) complexes
US4562275A (en) *	1984-03-23	1985-12-31	Bristol-Myers Co.	Antitumor platinum complexes
US4793986A (en) *	1987-02-25	1988-12-27	Johnson Matthey, Inc.	Macromolecular platinum antitumor compounds

1988
- 1988-06-06 SU SU884437541A patent/SU1685944A1/ru active
1989
- 1989-03-30 JP JP1506782A patent/JPH03501385A/ja active Pending
- 1989-03-30 EP EP89907376A patent/EP0374267A1/de not_active Withdrawn
- 1989-03-30 WO PCT/SU1989/000084 patent/WO1989011861A1/ru not_active Ceased
- 1989-03-30 FI FI900565A patent/FI900565A7/fi not_active IP Right Cessation
- 1989-06-05 CS CS893401A patent/CS340189A2/cs unknown
- 1989-06-06 CN CN89106291A patent/CN1040202A/zh active Pending

Also Published As

Publication number	Publication date
EP0374267A1 (de)	1990-06-27
SU1685944A1 (ru)	1991-10-23
WO1989011861A1 (fr)	1989-12-14
FI900565A0 (fi)	1990-02-05
FI900565A7 (fi)	1990-02-05
CN1040202A (zh)	1990-03-07
JPH03501385A (ja)	1991-03-28

Publication	Publication Date	Title
CA1243606A (en)	1988-10-25	Pharmaceutical compositions containing iron complexes of 3-hydroxy-4-pyrones
CA1253803A (en)	1989-05-09	Buccal and nasal compositions containing iron complexes of 3-hydroxy-4-pyrones
GB2146989A (en)	1985-05-01	Pharmaceutically active hydroxypyridones
JP3697210B2 (ja)	2005-09-21	二重ジカルボン酸ジアミノプラチン錯体の抗腫瘍誘導体、その調製方法、それを含む薬剤組成物及びその誘導体の適用方法
PT727430E (pt)	2001-11-30	Complexos de platina
WO1999042099A1 (en)	1999-08-26	Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof
RU2073031C1 (ru)	1997-02-10	Производные поли-1,4-этиленпиперазина, обладающие иммуномодулирующей, противовирусной и антибактериальной активностями
US4590001A (en)	1986-05-20	Platinum bound to transferrin for use in the treatment of breast tumors
PL128539B1 (en)	1984-02-29	Method of obtaining a platinum complex
US4594238A (en)	1986-06-10	Inhibition of undesired effect of platinum compounds
NZ197746A (en)	1985-08-16	Rescue composition for reducing toxic side effects of platinum(ii)complexes in treatment of neoplastic growths
JPH04507398A (ja)	1992-12-24	有機金属コバルト化合物及びその使用
WO1984004922A1 (en)	1984-12-20	Copper complex for treating cancer
CA1223202A (en)	1987-06-23	Fibronectin-physiologically active substance complex and method of preparation thereof
RU2345086C2 (ru)	2009-01-27	Способ получения цис-диаммонийдихлордигидроксоплатины (iv) и ее применение
AU2002325863B2 (en)	2006-11-23	Organometallic anti-tumour agent
US5087712A (en)	1992-02-11	Derivatives of platinum (ii) with polymethylsiloxane, method for preparing same and antitumor agent based thereon
USRE37534E1 (en)	2002-01-29	Pharmaceutical compositions
US3466312A (en)	1969-09-09	Derivatives of dialkyl-cysteines and allied compounds
JPH072679A (ja)	1995-01-06	腫瘍免疫治療剤
US6921824B1 (en)	2005-07-26	Ruthenium dimeric complexes suitable as antimetastatic and antineoplastic agents
GB2304712A (en)	1997-03-26	Complex
EP1722857A2 (en)	2006-11-22	Use of a compound having two gold(i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(i) atoms for the treatment of cancer
EP0186363A1 (en)	1986-07-02	Platinum complexes
SU713152A1 (ru)	1991-11-15	Свинцова соль @ -амино- @ -фенилпропионовой кислоты, про вл юща канцеролитическое действие